What is the appropriate enoxaparin dosing regimen when used as an adjunct anticoagulant during thrombolysis with streptokinase and tenecteplase, including adjustments for renal function, age, and body weight?

Enoxaparin Dosing with Fibrinolytic Therapy

When using enoxaparin as adjunctive anticoagulation during thrombolysis with tenecteplase or streptokinase, administer age- and renal-adjusted dosing as follows: for patients <75 years with normal renal function, give 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first two doses); for patients ≥75 years, omit the IV bolus and give 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first two doses); for all patients with creatinine clearance <30 mL/min regardless of age, give 1 mg/kg subcutaneously every 24 hours. 1

Dosing Algorithm by Patient Characteristics

Standard Dosing (Age <75 years, CrCl ≥30 mL/min)

• Initial IV bolus: 30 mg
• Maintenance: 1 mg/kg subcutaneously every 12 hours
• Maximum dose cap: 100 mg for the first two doses only
• Duration: Continue until revascularization or for 48 hours to 8 days of hospitalization 1, 2

Elderly Patients (Age ≥75 years, CrCl ≥30 mL/min)

• No IV bolus - this is critical to avoid intracranial hemorrhage
• Maintenance: 0.75 mg/kg subcutaneously every 12 hours
• Maximum dose cap: 75 mg for the first two doses only 1

The rationale for this age-based adjustment stems from the ExTRACT-TIMI 25 trial (n=20,506), which demonstrated that while enoxaparin reduced death and reinfarction compared to unfractionated heparin, there was a significant increase in intracranial hemorrhage in elderly patients receiving standard dosing 2. The ASSENT-3 PLUS trial further confirmed increased intracranial hemorrhage risk (2.20% vs 0.97%) in patients >75 years receiving full-dose enoxaparin with tenecteplase 3.

Severe Renal Impairment (CrCl <30 mL/min, any age)

• No IV bolus
• Maintenance: 1 mg/kg subcutaneously every 24 hours (not every 12 hours)
• This applies regardless of patient age 1

Enoxaparin is 71% renally excreted, and clearance decreases by 39% in severe renal impairment, leading to drug accumulation and bleeding risk 4, 5. The once-daily dosing prevents supratherapeutic anti-Xa levels while maintaining efficacy.

Thrombolytic-Specific Considerations

With Tenecteplase

The combination of tenecteplase with enoxaparin is extensively studied and represents the most validated pharmacoinvasive strategy 2. This pairing has been investigated specifically in the accelerated dosing regimen and shows reduction in reinfarction (3.5% vs 5.8%) and refractory ischemia (4.4% vs 6.5%) compared to unfractionated heparin 3.

With Streptokinase

Enoxaparin demonstrated superiority over unfractionated heparin when combined with streptokinase in the OASIS-6 trial, preventing death and reinfarction 2. The same age- and renal-adjusted dosing applies.

Critical Safety Warnings

Bleeding Risk Stratification

• Highest risk: Age ≥75 years receiving full-dose enoxaparin - always use reduced dosing
• High risk: Severe renal impairment (CrCl <30 mL/min) - always extend dosing interval to 24 hours
• Moderate risk: Mild-to-moderate renal impairment (CrCl 30-60 mL/min) - standard dosing acceptable for first 48 hours, but consider monitoring 4

Common Pitfalls to Avoid

1. Do not give IV bolus to patients ≥75 years - this single error accounts for most excess intracranial hemorrhages
2. Do not use twice-daily dosing in severe renal impairment - drug accumulation occurs rapidly
3. Do not exceed dose caps - 100 mg (or 75 mg in elderly) applies only to first two doses, not all doses
4. Do not use fondaparinux if PCI is planned - catheter thrombosis risk makes this contraindicated 1

Transition to PCI

If the patient proceeds to percutaneous coronary intervention:

• Last dose 8-12 hours prior or only one dose given: Administer 0.3 mg/kg IV bolus
• Last dose within 8 hours: No additional enoxaparin needed
• No prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus 1

Duration of Therapy

Continue enoxaparin until:

• Revascularization is performed (preferred endpoint), or
• Minimum 48 hours completed, or
• Maximum 8 days of hospitalization 2

The 2025 ACC/AHA guidelines and 2018 ESC guidelines both prioritize enoxaparin over unfractionated heparin as adjunctive therapy with fibrinolytics, citing superior efficacy in preventing reinfarction despite modestly increased bleeding when appropriately dosed 1, 2. The net clinical benefit (composite of death, reinfarction, and intracranial hemorrhage) favors enoxaparin when age- and renal-adjusted dosing is strictly followed 2.